Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance (vol 48, pg 1131, 2016)
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1546-1718
Volume Title
Publisher
Publisher DOI
Sponsorship
Cancer Research UK (C14303/A17197)
Cancer Research Uk (None)